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Abstract
Background: Adjuvants enhance or modify an immune response that is made to an antigen. An antagonist of the
chemokine CCR4 receptor can display adjuvant-like properties by diminishing the ability of CD4+CD25+ regulatory T cells
(Tregs) to down-regulate immune responses.
Methodology: Here, we have used protein modelling to create a plausible chemokine receptor model with the aim of using
virtual screening to identify potential small molecule chemokine antagonists. A combination of homology modelling and
molecular docking was used to create a model of the CCR4 receptor in order to investigate potential lead compounds that
display antagonistic properties. Three-dimensional structure-based virtual screening of the CCR4 receptor identified 116 small
molecules that were calculated to have a high affinity for the receptor; these were tested experimentally for CCR4 antagonism.
Fifteen of these small molecules were shown to inhibit specifically CCR4-mediated cell migration, including that of CCR4+ Tregs.
Significance: Our CCR4 antagonists act as adjuvants augmenting human T cell proliferation in an in vitro immune response
model and compound SP50 increases T cell and antibody responses in vivo when combined with vaccine antigens of
Mycobacterium tuberculosis and Plasmodium yoelii in mice.
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Introduction
Adjuvants are substances added to vaccines to enhance or
modify the concomitant immune response and induce protection.
Virtually all current human subunit vaccines incorporate adju-
vants in addition to pathogen-derived antigenic molecules. The
use of adjuvants has two main benefits. First, the increased
immune response provides better and longer lasting protection
against the pathogen and second, the use of an adjuvant allows the
dose and dosing regime of the antigen(s) to be decreased and
modulated, reducing the cost and logistical complexity of
administering vaccines. The principal adjuvants licensed for
human use are alum salts and oil-in-water emulsions.
Adjuvants work via many mechanisms and take many forms.
Many adjuvants act by stimulating pattern recognition receptors
(PRRs) present on cells of the innate immune system, which is the
primary bulwark against invading pathogens. PRRs have been
found to recognize pathogen associated molecular patterns
(PAMPs), which are molecules present in pathogens such as
bacterial lippolysaccharides or viral DNA or RNA that differ from
mammalian molecules and are thus seen as foreign [1]. Apart from
having an immediate function as the first line of defense, the innate
immune system also triggers adaptive cellular and humoral
immune responses. These provide immunological memory so that
the response is greater when the antigen or pathogen is re-
encountered. Development of robust protective immunological
memory is the central aim of vaccination. In the era of modern
vaccinology, adjuvants should have well-defined molecular targets,
interacting with specific receptors on cells that have capacity to
modulate the course, quality and intensity of the immune
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response. For receptors that exacerbate or initiate the immune
response, such as Toll-like receptors, we need to find adjuvants
with agonistic properties. Alternatively, for inhibitory or regulatory
receptors, then we need antagonists able to abrogate the
suppressive effect of cellular populations with inhibitory or
regulatory characteristics.
Receptor-targeted small molecule adjuvants (SMA) are among
the most under-explored types of immunomodulatory adjuvants.
Examples include: imidazoquinolines (Imiquimod and Resiqui-
mod), which target Toll-like receptors (TLRs), specifically TLR-7
and-8, and were developed as nucleoside analogues for anti-viral
or anti-tumour therapy; Bestatin (a tumour adjuvant acting as an
inhibitor of aminopeptidase N [CD13]); Levamisole and Bupiv-
acaine (both DNA vaccine adjuvants). Other examples of non-
macromolecular adjuvants include monophosphoryl-lipid A,
muramyl dipeptide, QS21, PLG, Seppic ISA-51 and CpG
oligonucleotides. Optimised CpG oligonucleotides, which target
TLR-9, are now entering late phase trials as adjuvants for the
poorly immunogenic Hepatitis B vaccine.
Hitherto, the search for novel adjuvants has by no means been a
systematic process. The number of potential targets is large and
the variety of adjuvants–macromolecules, natural products, small
molecules, and combinations thereof–has precluded such a
strategy. Focusing on SMAs targeting chemokine receptors, we
propose the use of virtual screening as a means of greatly
accelerating the process of adjuvant discovery in either an
academic or a commercial setting.
Three-dimensional virtual screening, whereby a large number
of small molecules are docked into the three-dimensional model of
a protein receptor, is an important tool in the field of drug
discovery and optimisation. The identification of potential lead
compounds from databases of small molecules significantly
reduces the time spent on experimental screening and is therefore
now an integral part of drug design. There is particular interest in
developing drugs which are agonists or antagonists of G-protein
coupled receptors (GPCR), a superfamily of transmembrane
proteins responsible for the transduction of a variety of
extracellular signals into an intracellular response [2,3].
Chemokine receptors are a family of GPCRs that transduce
signals from chemokines, leukocyte chemoattractant peptides
secreted by several different cell types both constitutively and in
response to inflammatory stimuli [4,5]. Chemokines can be
divided into 4 families based on the arrangement of highly
conserved cysteine residues in the amino terminus of the protein.
The largest families are the CC and CXC families; the former
contains a characteristic motif of two adjacent cysteine residues
within the protein sequence while in the latter they are separated
by a single amino acid. Chemokines and their receptors play a
pivotal role in numerous biological processes, including immune
homeostasis, inflammation, angiogenesis, hematopoiesis, brain
and heart development.
Chemokine receptors are viable targets for adjuvant discovery.
CCR4, which serves as the receptor for two chemokines (CCL17
and CCL22) [6], is of particular interest because it is expressed by
regulatory T cells (Tregs), a subset of T cells which normally
functions in the downregulation of immune responses [7–9]. While
elucidating all the diverse mechanisms by which Tregs inhibit
immune responses remains a subject of active investigation, a
principal means in which they function is through interaction with
antigen-presenting dendritic cells (DC) [10–13].
Tregs maintain DC in an immature state, in which they are
poor stimulators of T cell responses. Since CCR4-mediated
migration in response to DC-secreted chemokines is crucially
involved in DC-T cell interactions [9,14–16], CCR4 antagonism
could enhance immune responses by interfering with the
inhibitory function of Tregs. In addition, CCR4 antagonists may
possess the ability to alter the type of immune response generated,
based on the differential expression of CCR4 on T cell effector
subsets. In particular, CCR4 is expressed on Th2-type CD4+ T
cells which have been linked to allergic inflammatory diseases such
as asthma, atopic dermatitis and allergic rhinitis, but is not
expressed by Th1 T cells that typically are involved in cell-
mediated protection against infection. In keeping with a role for
CCR4 on Th2 cells, anti-CCL17 and anti-CCL22 antibodies have
both been observed to have efficacy in murine asthma models.
Given that Th1 and Th2 responses are mutually antagonistic,
CCR4 antagonists may act as adjuvants that direct the immune
response towards a Th1-type response.
Chemokines and other large peptide ligands bind the extracel-
lular loop scaffold, a combination of the extracellular loops and N
terminus of the receptor, and thus only partially penetrate the
transmembrane core [17]. Small molecule agonists and antago-
nists of the molecule do not interact with the extracellular loops
but instead occupy a cavity within the transmembrane region of
the receptor that corresponds to a typical ligand-binding site.
Many commercially successful compounds act as GPCR ligands
and display several commonalities: the biphenyl tetrazole moiety
is, for example, a common motif. However, the lack of sequence
homology between GPCR subgroups means that no generalisa-
tions can be assumed.
Several CCR4 small molecule antagonists have previously been
developed, primarily with the aim of reducing T cell migration to
sites of inflammation. These antagonists have primarily been
developed based upon heterocylic rings. Allen et al. [18] produced a
series of thiazolidinone derivatives that all take the form of three
components extending from a central ring, a general structure or
pseudo-pharmacophore similar to many previously identified
chemokine receptor antagonists (see Figure 1a). The components
take the form of a left side tethered amide, a right side amide and a
central aromatic ring. Optimisation of these three components
generated a series of inhibitors with a potency range of 100–
200 nM. Despite showing a good affinity for the CCR4 receptor,
Figure 1. Structure of the thiazoline (a) and lactam (b) derivatives.
doi:10.1371/journal.pone.0008084.g001
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the thiazolidinones showed poor in vivo absorption. Subsequently,
the thiazolidinone core was replaced by a lactam (see Figure 1b)
[19]. The replacement of a sulphur atom by a carbon removed from
the compounds a potential centre for oxidative metabolism.
Although the lactams were more efficiently absorbed and possessed
enhanced chemotaxic antagonism, they also had reduced potency.
Separately, a series of closely related quinazoline, quinoline and
isoquinoline derivatives (see Figure 2) were identified which were
also CCR4 receptor antagonists. The compounds inhibited
binding of radiolabelled CCL22 and CCL17 to CCR4 receptors
on the surface of CEM cells and also inhibited in vitro migration of
the cells in response to CCL17. Structural modification was
undertaken to separate CCR4 antagonism from the cytotoxicity of
the compounds by varying the central aromatic core and terminal
aromatic moiety. Subsequent optimisation trials significantly
reduced cytotoxicity while retaining antagonism.
Previously, structure-based virtual screening using homology
models of GPCRs has demonstrated its validity [20] by
constructing 3D models of three GPCR proteins (the Dopamine
D3, Muscarinic M1 and Vasopressin V1a receptors) and testing
their ability to identify molecules with agonistic and antagonistic
properties. Further work on 5-HT agonists demonstrated that the
most efficient method of library design for a GPCR screening
utilizes a combination of a ligand-based similarity search and
structure-based screening to identify molecules with binding
properties [21]. Amongst other studies, a virtual screening
protocol based on a GPCR model was used to identify
Cannabinoid bioactive antagonists [22].
Here, we use a combination of fuzzy ligand similarity, homology
modelling of the CCR4 chemokine receptor, and structure-based
virtual screening to identify affine small molecule ligands of
CCR4. Experimental validation in vitro confirms that these
molecules have antagonistic properties and are capable of
inhibiting the activity of Tregs. Further, in vivo validation is
consistent with these molecules acting as adjuvants.
Results
Homology Modelling
In the absence of an experimentally determined structure for the
CCR4 chemokine receptor, it was necessary to create a homology
model from related proteins with determined structures. The first
high resolution structure of a GPCR, bovine rhodopsin, was
published in 2000 by Palczewski et al. (see Figure 3a–b) [23].
Although there was strong evidence that all GPCRs had the same
overall structure, this was not confirmed until the publication of a
second GPCR structure, b2 adrenergic receptor (see Discussion) [24].
A comparison of these two structures shows that the transmembrane
region is conserved but that there is a significant difference in the
extracellular and intracellular regions [25,26]. The initial parts of this
study - model building and virtual screening - were conducted before
the b2 adrenergic receptor became available; thus bovine rhodopsin
was used as the template for CCR4.
Homology modeling is a four-step process by which homologues
are first identified and then form the structural template, the target
sequence is aligned to the template, a model is built with this sequence
and optimised, and, finally, the model is evaluated [27]. The structure
of CCR4, as is the case for all GPCRs, comprises seven a-helices in a
flattened two-layer structure joined by three intracellular and three
extracellular loops. The transmembrane region of the molecule is
composed of seven highly conserved segments of 20–30 consecutive
residues with a high degree of hydrophobicity. The transmembrane
sequences were predicted using a transmembrane prediction
Figure 2. Structure of the quinazoline, quinoline and isoquin-
oline derivatives where either X or Y or both equal N.
doi:10.1371/journal.pone.0008084.g002
Figure 3. The crystal structure of bovine rhodopsin.
doi:10.1371/journal.pone.0008084.g003
Table 1. The predicted transmembrane (TM), intracellular
loop (IL) and extracellular loop (EL) regions of the human
CCR4 protein.
N terminus mnptdiadttldesiysnyylyesipkpctkegi
TM1 kafgelflpplyslvfvfgllgnsvvvlvlfky
IL1 Klrs
TM2 mtdvyllnlaisdllfvfslpfwgyyaadq
EL2 Wfg
TM3 lglckmiswmylvgfysgiffvmlmsidrylaiv
IL2 havfslrart
TM4 ltygvitslatwsvavfaslpgfl
EL2 fstcyternhtycktkyslnsttw
TM5 kvlssleinilglviplgimlfcysmiirt
IL3 lqhcknekknk
TM6 avkmifavvvlflgfwtpynivlfletlve
IL3 levlqdctferyldyaiq
TM7 atetlafvhcclnpiiyfflgekfr
C terminus kyilqlfktcrglfvlcqycgllqiysa
dtpsssytqstmdhdlhdal
doi:10.1371/journal.pone.0008084.t001
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algorithm (see Table 1) and docked together using the bovine
rhodopsin structure as a scaffold.
Hydrophobic profiles, derived from GPCR multiple sequence
alignments, were used to assign helical transmembrane regions.
The extracellular and intracellular loops as well as the termini of
the molecule were harder to model due to the low homology
between CCR4 and bovine rhodopsin in this region, as well as the
limitations of loop modelling methods. Extended loop conforma-
tions have highly variable conformations and are particularly
difficult to model. The termini and loops were therefore added in
an extended conformation. Homology models of both the human
and mouse CCR4 structures were generated. Completed CCR4
structures were then inserted into optimised lipid bilayers [28,29]
and bad contacts between the protein and lipid were eliminated.
The protein-ligand complexes were fully solvated and an energy
minimisation simulation was used to optimise the protein
structures (see Figure 4a–b).
Virtual Screening
At its most general, a pharmacophore summarizes structural
information common to ligands exhibiting a particular activity.
Based upon previously determined antagonists for chemokines, we
devised a set of screens that mimicked the behaviour of a low-level
pharmacophore: it specified that molecules should have molecular
weight .500, contain at least two 5- or 6- membered aromatic
rings, and at least one nitrogen atom. The CHEMBRIDGE,
TIMTEC and SPECS databases were scanned using this
pharmacophore and 13,000 compounds were thus selected for
evaluation by docking. The ligands were evaluated using the
GOLD docking program [30] using the Goldscore fitness function.
Previously, residues within the transmembrane region that are
involved in the binding region of human CCR4 have been
identified by mutational analysis; they include: Leu 42 and Tyr 46
(TM1), Trp 45 (TM2), Ile 113, Tyr 117 and Phe 121 (TM3), Ser
203 and Ile 206 (TM5), Tyr 258, Asn 259 and Leu 262 (TM6) and
Glu 290 (TM7). The residues implicated in the receptor-ligand
binding identified a cavity within the transmembrane region of the
CCR4 receptor corresponding to a typical ligand-binding site [31].
The cavity forms the shape of a distended teardrop with a size and
relative disposition defined by relative positions of the seven
transmembrane helices.
Two protein models were generated using homology modeling:
human CCR4 and mouse CCR4. Manual docking of known
chemokine ligands was consistent with a common mode of
antagonist binding for both receptors. For both human and mouse
receptors, GOLD was directed to dock each ligand within the
cavity by specifying that the docking must occur within 4 A˚ of at
least one the specified residues. Versus the human receptor, the
highest ranked molecule had a high Goldscore value of 71.03. For
logistic reasons, the top 116 were selected based on the Goldscore
versus human CCR4. The lowest ranked compound had a
Goldscore of 54.69. The 116 molecules were tested in vitro for
CCR4 receptor antagonism. For these compounds, scores versus
mouse CCR4 were decreased by 10; overall, mouse and human
Goldscores had a correlation coefficient of 0.49 (data not shown).
Fifteen of the small molecules were shown to inhibit significantly
in vitro CCR4-mediated migration at low concentrations, mediat-
ing 50% inhibition of migration at low nanomolar level or below
(see Table 2). The docked structures were minimized again in
order to improve their orientation within the groove. The small
molecules did not have standard parameters so they were
calculated using the program antechamber [32]. The residues that
contact each of the small molecules are shown in Table 3.
In Vitro Validation
Upon receiving maturation and activation associated signaling,
DC secrete CCL22 and CCL17, the ligands for CCR4 [33]. The
binding of these ligands to CCR4 helps to guide Tregs towards
DC, mediates contact between these two cell types and thus
inhibits activation of DC and the DC-mediated T cell response. If
CCR4+ Tregs fail to effectively compete with naive T cells for
access to DC because CCL22 and CCL17-binding to CCR4 is
blocked, this should result in firm contact between T-DC and
increased activation and differentiation of vaccine antigen-specific
effector T cells. As reported elsewhere [34], 15 of the 116 top
ranked molecules from virtual screening specifically inhibited
CCL22-mediated chemotaxis of a CCR4+ human Caucasian
acute T lymphoblastoid leukaemia cell line CCRF-CEM, yet had
no effect on migration mediated through CXCR4, which is also
Figure 4. The CCR4 homology model inserted into a LMP and
fully solvated. The water atoms (red) form a box around the protein
and DPP atoms (blue).
doi:10.1371/journal.pone.0008084.g004
Table 2. Inhibition data from 16 small molecules selected by
virtual screening. Antagonists shown to inhibit Treg migration
shown in bold.
Compound MW
Concentrations required
to inhibit 50% of CCRF-
CEM cell migration in the
chemotaxis assay (M)
CB4 534.1135 1.80610209
CB16 506.3258 2.49610211
CB20 599.8731 5.11610210
CB28 548.6657 3.13610210
SP20 501.3615 1.14610211
SP27 598.0112 2.75610210
SP30 525.4454 5.90610211
SP32 561.4423 3.33610211
SP35 536.4247 3.55610212
SP40 571.4658 7.90610212
SP45 628.8046 5.14610212
SP46 565.9365 2.34610212
SP48 617.5108 1.76610211
SP50 531.4835 9.78610211
TT3 636.441 8.59610212
doi:10.1371/journal.pone.0008084.t002
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expressed on CCRF-CEM cells, demonstrating their selectivity for
CCR4. Importantly, 6 molecules (SP45, SP50, CB28, TT3, SP46,
SP40) were shown directly to block CCR4-mediated migration of
human Tregs in response to CCL17 and CCL22. The structures
of these 6 small molecules are shown in Figure 5. All 6 antagonists
inhibited significantly CCL22-mediated Treg migration and up to
49.8% inhibition was observed when Tregs from six individual
donors were examined, whereas none of the 6 compounds affected
cell viability (Figure 6). In addition, all of the molecules inhibited
Treg migration in response to another CCR4 ligand, CCL17 (up
to 57.2% inhibition of migration) as well as CCL22- and CCL17-
mediated migration of human Th2 cells. The CCR4 antagonists
enhanced significantly DC-mediated human T cell proliferation in
an in vitro model of immune response when Tregs were present in
the CD4+ T cell pool, consistent with the hypothesis that
molecules that inhibit Treg migration should possess adjuvant
activity.
In Vivo Validation
Prior to testing the adjuvant activity of CCR4 antagonists in vivo,
we first studied the ability of antagonists to inhibit the CCL22-
mediated migration of the murine CCR4+ T cell hybridoma B9.1.
These migratory assays were undertaken using a similar protocol
to that used for human cells. Four of the 15 compounds (CB20,
SP46, SP50 and TT3) were found to inhibit the migration of B9.1
cells up to 55%. We then examined the influence of one of these
compounds (SP50) on the immune response to vaccination in
mice. The impact of CCR4 antagonists on the cellular immune
response was investigated using a CMV vector expressing
Rv1818c (CMV1818c) or Rv3812 (CMV3812) proteins from
Table 3. Contact residues for the eight selected small molecules. All residues contain are within 4 A˚ of a ligand atom. Residues in
bold are common to all six ligands.
Residue Transmembrane TT3 SP50 SP46 SP40 SP45 CB28
Leu 92 TM2
Tyr 117 TM3 X X X X
Phe 121 TM3 X X X X X
Tyr 122 TM3 X X X
Phe 126 TM3 X
Phe 167 TM4 X
Leu 201 TM5 X
Ser 202 TM5 X
Ser 203 TM5 X
Leu 204 TM5 X
Glu 205 TM5 X X X
Ile 206 TM5 X X X X X X
Asn 207 TM5 X
Leu 209 TM5 X X
Gly 210 TM5 X
Trp 255 TM6 X X X X
Pro 257 TM6 X X X X X
Tyr 258 TM6 X X X X X X
Asn 259 TM6 X X
Ile 260 TM6 X
Val 261 TM6 X X X X
Leu 262 TM6 X X X X X X
Phe 263 TM6 X
Thr 266 TM6 X
Ala 285 EL3 X X
Ile 286 EL3 X X X
Gln 287 EL3 X X X X X
Ala 288 TM7 X
Thr 289 TM7 X
Glu 290 TM7 X X X X X X
Thr 291 TM7 X
Ala 293 TM7 X X
Phe 294 TM7 X X X X
Val 295 TM7 X X X X
doi:10.1371/journal.pone.0008084.t003
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Mycobacterium tuberculosis [35]. Simultaneous administration of SP50
with CMV1818c or CMV3812 enhanced significantly the
Rv1818c and Rv3812-specific CD4+ T cell proliferative immune
response (Figure 7a). Interestingly, no significant changes were
observed in the percentage of Tregs in the spleen of mice injected
with antagonist alone (3.75–4% CD4+FoxP3+ T cells in SP50
Figure 5. The conventional 2D representation of the six selected ligands showing inhibitory properties for CCR4-mediated
migration.
doi:10.1371/journal.pone.0008084.g005
Figure 6. Assessment of CCRF-CEM cell viability by propidium iodide (PI) and annexin V labeling following treatment with CCR4
antagonists. Propidium iodide (PI) labels cells lacking intact plasma membranes and hence at an advanced stage of cell death. Annexin V labels cells
at early and late stages of apoptosis. Plots show representative data for cells cultured in medium alone or in medium to which solvent (DMSO) or
antagonist has been added. Numbers indicate percentage of cells in each quadrant.
doi:10.1371/journal.pone.0008084.g006
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injected mice versus 4–4.5% CD4+FoxP3+ T cells in control
groups), thus confirming that CCR4 antagonists per se do not
modify the population of Tregs.
The potential for CCR4 antagonists to enhance antibody
responses was examined using Human Adenovirus 5 encoding the
42 kD region of the merozoite surface protein-1 (Ad-MSP-142)
from Plasmodium yoelii. Ad-MSP-142 induces a strong antibody
response after two weeks to the 19 kD fragment of MSP-1 (MSP-
119), which is thought to mediate protective immunity [36,37].
Notably, despite the considerable intrinsic immunogenicity of this
vaccine, the titre of MSP-119-specific IgG was significantly
increased by co-injection of SP50 (Figure 7b). Although the three
other compounds tested had no effect, we did not carry out
thorough dose response experiments nor did we investigate the
timing of adjuvant relative to antigen administration. However
SP46 and TT3 increase cellular immune responses to mycobac-
terial antigens as previously reported suggesting that these
antagonists selectively potentiate cellular immunity [34].
Discussion
Kornbluth and Stone have recently hailed a new golden age of
vaccine discovery focusing on the exploitation of adjuvants as
immunomodulators able to enhance immunogencity of subunit
and peptide-based vaccines [38]. They group adjuvants into
stimulatory and suppressive immunomodulators. Immunostimula-
tory adjuvants include Toll receptor agonists; agonists of CD40
and other members of the TNF receptor superfamily such as
OX40L, 4-1BBL, CD30L, LIGHT, CD27L/CD70, and GITRL;
and agonists of the Nod-like Receptor system. Adjuvants that
function by modulating immunosuppressive arms of the immune
system include neutralizing antibodies to anti-inflammatory
cytokines or antagonists to molecules such as CTLA-4 that
provide negative signaling to innate immune cells. Our molecules
also fall into this second category.
Compared to biogenic macromolecules or synthetically intracta-
ble natural products, small molecule adjuvants have many potential
advantages. As small drug-like molecules, it may be possible to tailor
their properties precisely, using the standard pharmaceutical toolkit
- structure- and ligand-based virtual screening, parallel synthesis,
and medicinal chemistry - properly to explore their specificity and
properties. It should also be possible to develop an understanding of
how to manipulate rationally the structure of these compounds so as
to generate molecules with improved in vivo characteristics. While a
drug with a once-a-lifetime or once-a-year dosing does not require
all the properties that might be expected in a modern drug, altering
them to be as close as possible to optimum pharmacokinetic
properties would be advantageous.
Here we have used virtual screening to identify CCR4
antagonists which act as adjuvants for both cellular and humoral
immune responses. Effective three-dimensional virtual screening is
reliant upon an accurate model of the receptor. There are very few
experimentally-determined high-resolution structures of membrane
proteins available in the Protein DataBank due to difficulties in their
over-expression, purification and crystallization [39]. Where the
similarity between sequences is less than 30%, it can be extremely
difficult to align sequences in a certain and unambiguous way; this
region of similarity is often described as the ‘twilight zone’. The
lower the sequence similarity between the target and template
protein, the more difficult it becomes to undertake a successful
alignment between them. Despite the low sequence homology
(22.7%) between bovine rhodopsin and the chemokine receptors, it
was possible to identify the transmembrane regions within the
chemokine sequence and build them up as idealised a-helices. This
is because all GPCRs share a common pattern of hydrophobicity
and similarity of structure even when there is sequence divergence;
thus a reasonable model of the transmembrane region of the
chemokine receptor can be generated. The validity of using
homology modelling to generate GPCR structures is supported by
comparison with the b2-adrenergic receptor. It is very similar in
terms of the relative orientation of the seven transmembrane helices,
suggesting a degree of universal conformity for the transmembrane
region of GPCRs. The conformation of the second extracellular
loop, which often constitutes the top of the ligand binding site, is,
however, quite different in the two structures.
Attempts to develop small molecules antagonists for chemokines
have focused on the CCR5 and CXCR4 receptors because an
antagonist might have therapeutic potential in the inhibition of
HIV-1 virus uptake [3]. Docking studies using the antagonist
Figure 7. CCR4 antagonists enhance cellular and humoral
responses in mice. (a) Effect of SP50 on T cell priming to
Mycobacterium tuberculosis protein antigens Rv1818c or Rv3812.
Splenocytes (0.56106) from mice immunised with the indicated
proteins+SP50 or DMSO were cultured in vitro in the presence of 5 mg/
ml of either Rv1818c or Rv3812 recombinant proteins for 5 days. Cells
from three mice per group were tested individually in quadruplicate
wells. Antigen-specific T cell proliferation was measured by thymidine
incorporation assay and data are presented as stimulation index (SI, mean
cpm of the antigen stimulated wells/mean cpm of control wells).
Significant differences are indicated by asterisks * p,0.05. The results are
from one experiment. (b) IgG serum antibody responses against MSP-119
measured by ELISA 14 days post vaccination with Ad-MSP-142 plus the
indicated compounds or DMSO control. Three mice per group were
tested individually. Columns represent the mean6SD. Significant
differences are indicated by asterisks * p,0.05. Similar results were
obtained in two independent experiments.
doi:10.1371/journal.pone.0008084.g007
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TAK-779 [40] and a model of the related CCR5 receptor
identified a region of the binding pocket that may act as a
conserved binding point for chemokine antagonists sharing an
ammonium group [41]. The benzyl-pyron-ammonium-group of
TAK-779 interacts with transmembrane helices 1, 2 and 7.
Selectivity of TAK-779 was analysed using site-directed mutagen-
esis and is in agreement with observed structure-activity
relationships. The binding is dependent on the ammonium groups
being in close contact with the conserved CCR5 residue Glu 283
(Glu 290 in CCR4). The introduction of a single point mutation
into a functionally active receptor can lead to a decrease in binding
affinity, indicating the residue is vital to the ligand-receptor
interaction. It is likely that high affinity receptor-ligand binding is
partly dependent on strong interactions with a few key residues.
There are also non-conserved residues within transmembrane
regions TM3, TM5 and TM6 that can impair receptor selectivity.
Previous attempts to model the ligand interactions of the CCR5
ligand identified the same cavity within the chemokine structure
but showed the binding of the ligand to be primarily dependent on
interaction with the TM1, TM2, TM3 and TM7 helices. The
docked structure of CB20 in the human CCR4 receptor homology
model is shown in Figure 8a–b. The docked models indicate that
the ligands maintain key interactions with the TM7 but not the
TM1 and TM2 helices. Residues Ile 206, Tyr 258 and Glu 290 (on
the TM5, TM6 and TM7 helices respectively) seem to be
fundamental to the interaction, in particular, Glu 290; this
interacts with positively charged moieties on the bound ligand.
The other end of the molecule is predominantly hydrophobic and
interacts with Ile 206. The molecules are all linear and stretch
across the length of the groove to interact with both the TM5 and
TM7 helices. There is also a slight interaction with extracellular
loop III (285–287). It is possible that a less linear molecule, such as
TAK-799 that binds the CCR5 receptor, would not position itself
directly across the groove. It is also possible that the parameters
defined by antechamber do not allow our small molecules sufficient
flexibility to optimize their position within the cavity [32]. The
human CCR4 model was subsequently modified to produce a
mouse CCR4 receptor model. There is strong homology between
the two structures and the extended tear drop structure of the
active site is maintained.
When tested in vivo with vaccines in mice, enhanced immuno-
genicity was observed with the CCR4 antagonist SP50 acting as an
adjuvant for both cellular and humoral immune responses. The
lack of effects on the humoral response of the three other
compounds tested (CB20, SP46 and TT3) might be because an
inappropriate dose or time of administration was used, although
SP46 and TT3 increase cellular immune responses to mycobac-
terial antigens when used in combination with Modified Vaccinia
Ankara expressing Ag85A from M. tuberculosis (MVA85A) [34].
Sp50 has previously been demonstrated to potentiate the humoral
response to another antigen, recombinant hepatitis B surface
antigen (HBsAg) [34], which is a poorly immunogenic antigen
often requiring several immunizations to generate protective
antibody titers in humans. Strikingly in the present experiments,
in addition to its effect on weakly immunogenic HBsAg, SP50
potentiates cellular and humoral responses to Mycobacterial
antigens and a malaria antigen administered in viral vectors that
have strong inherent adjuvanticity. We suggest that this augmen-
tation may be because these viral vectors mediate adjuvant effects
by ligating pattern recognition receptors while SP50 interferes with
regulatory cell function.
If CCR4+ Tregs fail to compete effectively with naive T cells for
access to DC because CCL22 and CCL17-binding to CCR4 is
blocked then this should result in the reduced influence of Tregs
Figure 8. CB20 ligand docked into the CCR4 homology model.
doi:10.1371/journal.pone.0008084.g008
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on both DC and T cell populations and as a consequence an
increased antigen-specific cellular and humoral response. In fact,
several experimental models have demonstrated that inhibition of
Treg function results in markedly superior immune responses to
foreign and tumour antigens, virus infection and vaccines [42–44].
However, these experiments were typically performed by using
therapeutic monoclonal antibodies either to deplete Tregs or to
block CD25, an IL-2 receptor a-chain expressed by Tregs.
We believe that CCR4 antagonists may have advantages over
these methods of blocking Treg functions. First, antibody-
mediated inhibition of Treg function might result in severe
adverse effects, since Tregs are required for maintenance of
immune tolerance. For example, injection of anti-CD25 antibodies
alone or in combination with anti-CTLA-4 antibodies into normal
animals is known to induce localized autoimmune disease [45,46].
Second, as compared to small molecules, therapeutic IgG
monoclonal antibodies have a longer half-life (about 3 weeks in
humans). Indeed, we did not observe any significant changes in the
Treg population in the spleen of mice injected with antagonist
alone, thus confirming that CCR4 antagonists do not delete the
Treg population. Therefore we suggest that it is likely that CCR4
antagonists perform their adjuvant-like function by transiently
inhibiting Treg migration. In addition, our in vitro experiments
support the proposition that CCR4 antagonists could function
similarly in humans. Thus, in a transwell system, exposure of T
cells to CCR4 antagonists enhanced their proliferation in response
to mature DC. This model may mimic the early events of an
immune response, where inhibition of Treg recruitment to DC
would lead to an increased antigen-specific T cell response.
Aluminum adjuvants are the only adjuvants licensed for human
vaccines in the USA. The immune responses elicited by aluminum
adjuvants are not likely to confer protection against diseases such as
malaria, tuberculosis, and cancer for which Th1 and MHC class I
restricted cytotoxic T lymphocyte (CTL) responses are essential for
protection [47]. Therefore, adjuvants that can target specific
receptors and elicit protective Th1 and CTL immune responses are
desirable. Thus, several novel adjuvants, including molecules that
target TLRs and NLRs which potently activate antigen presenting
cells and Th1 type immune responses are under consideration
[48,49]. Our in vivo results in experimental models demonstrate that
small molecule antagonists to CCR4 enhance both cellular and
humoral immune responses to vaccine antigens. Thus, in the future
they can be considered for use with novel vaccine candidates either
alone or in synergistic combination with other adjuvants.
In trying to identify novel agonists and antagonists for a
receptor, computational chemistry allows a large number of
compounds to be screened rapidly. This can act as a filtering
system allowing molecules that have been calculated to have
affinity for the receptor to be targeted. Virtual screening explores
the chemical diversity of potential ligands and structural
constraints imposed by the receptor. GPCR agonists and
antagonists tend to be larger molecules than commonly favoured
in drug design. Helices 3, 5, 6 and 7 are responsible for the
majority of the side chain interactions with the bound ligand. It is
likely that the CCR4-ligand interactions depend on strong
interactions in a few key residues, such as Ile 206, Tyr 258 and
Glu 290, as well as weaker ones with the other residues in the
CCR4 cavity. Site-directed mutations could be used to establish
those residues which are responsible for interacting with particular
functional groups, facilitating an augmented understanding of
ligand-receptor structure-activity relationships (SAR). Site directed
mutations in the TM 5, 6 and 7 regions would be useful in further
determining the nature of the receptor-ligand interaction and help
towards optimising CCR4 antagonists. All of the ligands have a
molecular weight .500 which contravenes Lipinski’s rule-of-five
regarding the maximum size of a potential drug candidate [50].
Further work will target reducing the molecular weight of the
molecules, as well as maximizing their antagonistic properties.
Three-dimensional virtual screening is now known to be an
effective and economical way of identifying potential lead
compounds with desired activity [51]. In this study, about 14%
of the small molecules identified by virtual screening were shown
to have a degree of antagonism, remarkable considering the
receptor structure was not an experimental structure but a
homology model built from a related structure with a low degree
of sequence homology. The inclusion of an explicitly rendered
lipid bilayer into the energy minimisation simulation may have
helped in optimising the quality of the structure. The identified
antagonists have been shown to be both potent and specific for the
desired target receptor.
Our results re-emphasize the power of virtual screening, by
systematising the discovery of small molecule adjuvants through
targeting receptors implicated in the innate immune response or in
regulating the adaptive immune response. Using virtual screening,
we have identified CCR4 antagonists acting as adjuvants for both
cellular and humoral immune responses. When our molecules
were tested in vivo with vaccines in mice, enhanced immunoge-
nicity was observed with SP50. The enhancing effects observed in
these experiments are particularly striking given that the vaccine
vectors employed are known to be intrinsically immunogenic
[35,37]. Within vaccinology - as it is within drug design and
discovery–structure-based virtual screening is an approach of
unprecedented power and scope; only wide deployment is needed
for virtual screening to realize its full potential.
Methods
Model Building
The transmembrane sequences of human CCR4 protein were
docked together using the bovine rhodopsin structure as a scaffold.
Attwood developed diagnostic fingerprint for rhodopsin-like
GPCRs based on common patterns of conservation in the seven
transmembrane regions [52]. WHATIF was used to generate the
helical transmembrane sections of human CCR4 [53]. The
orientation of the helices is calculated with respect to a lipid
environment so that hydrophobic faces are orientated into the
membrane phase and hydrophilic faces point into the lumen of the
protein. The translational and rotational orientation of each helix
in the transmembrane bundle is critical to the nature and
conformation of the binding site. Hydrophobic areas of the
transmembrane bundle will be orientated such that their peak
hydrophobicity lies centrally within the lipid plane. This position
corresponds to the so-called lipid midpoint plane (LMP). A model
of mouse CCR4 was constructed using the optimised human
CCR4 structure as a template.
Energy Minimisation
Hydrogen atoms were added to the human CCR4 structure and
the system was fully solvated using water molecules in the TIP3
model [54] by the AMBER program leapi [32]. This created a
solvent box with dimensions of approximately 40 A˚ by 50 A˚ by
120 A˚ and approximately 110,000 atoms (See Figure 4a–b). All
atoms in the simulation were explicitly represented. Two known
conserved disulphide bonds between Cy29–Cys276 and Cys110–
Cys187 were built into the structure [55]. The energy of the solvated
molecular complex was minimised using the general AMBER force
field with a steepest descent method that was continued for 50,000
time steps (one time step–one femtosecond) or until the RMSD had
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fallen below 0.01 A˚ between successive time steps. In the first stage
of minimisation, the transmembrane region and lipid region were
frozen in order to allow the loops to order themselves using the
transmembrane scaffold. In the second stage, simulated annealing
was carried out on the minimized structure. At this stage, all atoms
in the systems were allowed free movement. The system was
annealed by raising the temperature of the system from 0 K to
500 K over a period of 40,000 time steps and maintaining that
temperature for a further 30,000 time steps. The system was then
cooled to 0.2 K over a period of 230,000 time steps before being
rested at 1 K for a further 300,000 time steps. The CPU of each
individual simulation was approximately 500 hours on a 6-
processor R12000 SGI Origin 2000. All minimisation and
annealing steps were performed using the sander program [32].
The process was repeated for the mouse CCR4 model. The docked
small molecules were run under the same conditions and time
period as the initial energy minimization. Antechamber was used to
generate parameters for the small molecules.
Virtual Screening
A database containing structures from a variety of compound
suppliers was constructed within UNITY [56] and screened for
potentially reactive and undesirable molecules [57]. The resulting
database contained ,450 K molecules. This was pre-screened
using a simple pseudo-pharmacophore derived from properties of
known Chemokine antagonists: compounds must have a MW.500
and contain two or more 5 or 6 membered aromatic rings and one
or more nitrogen atoms. Thirteen thousand compounds were thus
selected, and their 3D structure built using CORINA [58], which
were tested for interaction with the two modelled CCR4 structures
using the GOLD docking program and the Goldscore fitness
function. The ligands were docked within a predicted cavity in the
transmembrane region of human and mouse CCR4.
Cell Lines
The human Caucasian acute T lymphoblastoid leukaemia cell line
CCRF-CEM (European cell culture collection) and murine T cell
hybridoma B9.1, specific for the immunodominant peptide
HEL103–117 [59], were cultured in RPMI 1640 with 10% fetal
calf serum. Both cell lines express CCR4 and migrate in response to
CCR4 ligands.
Generation of Dendritic Cells
Peripheral blood mononuclear cells (PBMC) were isolated from
buffy coats, purchased from the North London Blood Transfusion
Centre, by Ficoll-Hypaque density gradient centrifugation. Ethical
approval for use of this material was obtained from the Compton
Human Subjects Committee. Monocytes were purified by positive
selection using CD14 beads (Miltenyi Biotech, Surrey, UK). For
generation of DC, monocytes were cultured for 6 days in the presence
of RPMI 1640 supplemented with 10% FCS, 50 U/ml penicillin,
50 mg/ml streptomycin, recombinant human (rh) IL-4 (500 IU/106
cells) (R&D Systems Europe, Abingdon, UK) and rhGM-CSF
(1000 IU/106 cells) (Immuno Tools, Friesoythe, Germany).
Isolation of Human CD4+CD25+ Regulatory T Cells
CD4+CD25+ Tregs were isolated PBMC using a kit from
Miltenyi Biotech. The purity of isolated regulatory T cells was over
95% as assessed by flow cytometry.
Generation of Th2 Cells
Naı¨ve CD4+ CD45RA+ T cells were purified from PBMC in a 2-
step process using magnetic beads (Miltenyi Biotech). First,
untouched CD4+ T cells were isolated by negative selection.
Second, CD45RO+ T cells were depleted using CD45RO beads.
The remaining CD4+ CD45RA+ T cells were added to 24-well
tissue culture plates that were pre-coated with 10 mg/ml anti-CD3
and anti-CD28 mAbs (R&D systems Europe). Cells were cultured in
RPMI 1640/10% FCS in the presence of 10 mg/ml neutralizing
anti-IL-12 and IFN-c mAbs, 10 ng/ml rhIL-2 and 20 ng/ml rhIL-
4 (all from R&D systems). After 3 days, 0.5 ml of 4 ng/ml IL-2 was
added to the cultures. At day 6, cells were harvested, washed and the
stimulation cycle repeated. The cells were analyzed for Th2
differentiation and CCR4 expression before use in experiments.
In Vitro Assay to Measure Antagonist Activity of
Molecules
Chemotaxis assay was performed by measuring the ability of
molecules to inhibit cellular migration through a 5 mm pore
polycarbonate filter in 24-well transwell chambers (Costar, Cam-
bridge, MA). Chemokines (R&D systems) were placed in lower
chambers in a 600 ml volume and cells were placed in upper chambers
in a 100 ml volume. After 2 h incubation at 37uC, cells in the lower
chamber were recovered and counted using a FACSCalibur (Becton
Dickinson, Mountain View, CA) [34]. Preliminary chemokine
titration experiments established optimal doses for chemotaxis: (1)
for CCRF-CEM cells, 6 nM CCL22 and 3 nM CCL17 or CXCL12;
(2) for Tregs and Th2 cells, 1.2 nM CCL22 or CCL17. To measure
the concentrations required to inhibit 50% of cell migration in the
chemotaxis assay, graded doses of antagonists were added to a
constant concentration of CCL22. To assess CCR4 antagonism,
candidate antagonist compounds (10 nM) were mixed directly with
chemokines as indicated. Percent inhibition of chemotaxis by CCR4
antagonists was calculated in relation to controls treated with solvent
(DMSO) alone as follows: ([no. cells migrated in the presence of
DMSO–no. cells migrated in the presence of antagonist]/no. cells
migrated in the presence of DMSO)6100.
Animals and Immunizations
The construction, design and preparation of pFLAG CMV4
mammalian expression vectors (Sigma-Aldrich) expressing M. tubercu-
losis Rv1818c (CMV1818c) and Rv3812 (CMV3812) has been
described previously [35]. SP50 was dissolved in DMSO and mixed
with each vaccine to give a final concentration of 1 mM compound in
10% DMSO. 6–8 week old Balb-c mice were immunized intramus-
cularly in the hind leg with 25 ml vaccine/SP50 mix containing 50 mg
CMV1818c or CMV3812 DNA three times at weekly intervals. A
fourth booster dose of 25 mg of purified recombinant proteins
(Rv1818c and Rv3812) expressed in E.coli [35] was given subcutane-
ously with SP50. The experiments were performed as per the rules of
the Indian Institute of Science (Bangalore, India).
Human adenovirus type 5 (AdHu5) expressing the 42 kDa
region of merozoite surface protein-1 (Ad-MSP-142) from P. yoelii
was also used [37]. The adjuvant compounds were dissolved in
DMSO and were mixed with each vaccine to give a final
concentration of 1 mM compound in 10% DMSO. 6–8 week old
female BALB/c mice were immunized once intramuscularly in the
hind leg with 25 ml of vaccine/compound mix containing 561010
vp of Ad-MSP-142 per mouse. They were bled 14 days later.
Experiments with Ad-Msp-142 were approved by the animal
ethical committee of Oxford University and fully complied with
the relevant Home Office guidelines.
T Cell Proliferation Assay
Splenocytes were harvested from mice immunized with
mycobacterial antigens (Rv1818c and Rv3812) 72 hrs post last
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booster. 0.56106 splenocytes were cultured in presence of 5 mg/ml
of either Rv1818c or Rv3812 recombinant proteins for 5 days.
Three mice per group were tested individually. The T cellular
proliferative response was measured by thymidine incorporation
assay following a 16 h pulse with 1 mCi of [3H]thymidine.
Radioactive incorporation was measured by standard liquid
scintillation counting and results expressed as counts per minute
(cpm, mean6SD of triplicate values). The data are presented as
stimulation index (SI, Mean cpm of the antigen stimulated wells/
Mean cpm of control.
ELISA
Serum was collected two weeks after Ad-MSP-142 vaccination
and analysed by indirect ELISA as previously described using
recombinant GST-MSP-119 or GST control followed by alkaline
phosphatase-conjugated anti-mouse whole IgG (Sigma) [60].
Endpoint titres were taken as the x-axis intercept of the dilution
curve at an absorbance value 3 x standard deviations greater than
the OD405 for naı¨ve mouse serum (typical cut off OD405 for
positive sera = 0.15).
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